-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Shanghai Xuerong Biotechnology Co.,Ltd.'s (SZSE:300511) Stock Price Dropped 11% Last Week; Individual Investors Would Not Be Happy
Shanghai Xuerong Biotechnology Co.,Ltd.'s (SZSE:300511) Stock Price Dropped 11% Last Week; Individual Investors Would Not Be Happy
A look at the shareholders of Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 59% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
While insiders who own 25% came under pressure after market cap dropped to CN¥3.4b last week,individual investors took the most losses.
Let's take a closer look to see what the different types of shareholders can tell us about Shanghai Xuerong BiotechnologyLtd.
View our latest analysis for Shanghai Xuerong BiotechnologyLtd
SZSE:300511 Ownership Breakdown September 30th 2022What Does The Institutional Ownership Tell Us About Shanghai Xuerong BiotechnologyLtd?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
As you can see, institutional investors have a fair amount of stake in Shanghai Xuerong BiotechnologyLtd. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Shanghai Xuerong BiotechnologyLtd, (below). Of course, keep in mind that there are other factors to consider, too.
SZSE:300511 Earnings and Revenue Growth September 30th 2022Hedge funds don't have many shares in Shanghai Xuerong BiotechnologyLtd. Looking at our data, we can see that the largest shareholder is the CEO Yongping Yang with 21% of shares outstanding. With 4.4% and 4.3% of the shares outstanding respectively, Zhejiang Invest Equity Investment & Management Co., Ltd. and Shenzhen Yuntu Asset Management Service Co., Ltd. are the second and third largest shareholders.
A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
Insider Ownership Of Shanghai Xuerong BiotechnologyLtd
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our information suggests that insiders maintain a significant holding in Shanghai Xuerong Biotechnology Co.,Ltd.. Insiders have a CN¥828m stake in this CN¥3.4b business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.
General Public Ownership
The general public, who are usually individual investors, hold a substantial 59% stake in Shanghai Xuerong BiotechnologyLtd, suggesting it is a fairly popular stock. This level of ownership gives investors from the wider public some power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for Shanghai Xuerong BiotechnologyLtd (of which 2 are concerning!) you should know about.
Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
看看上海雪荣生物科技股份有限公司(深交所股票代码:300511)的股东,我们就知道哪个集团最强大。我们可以看到,个人投资者拥有公司最大的股份,拥有59%的股份。换句话说,该集团面临着最大的上行潜力(或下行风险)。
虽然在上周市值跌至人民币34亿元后,持有25%股份的内部人士面临压力,但个人投资者承担了最大的损失。
让我们仔细看看不同类型的股东对上海雪荣生物科技有限公司有什么启示。
查看我们对上海雪荣生物科技有限公司的最新分析
深圳证交所:300511所有权明细2022年9月30日关于上海雪荣生物科技有限公司,机构持股告诉了我们什么?
机构投资者通常将自己的回报与经常跟踪的指数的回报进行比较。因此,他们通常确实会考虑收购被纳入相关基准指数的较大公司。
如你所见,机构投资者在上海雪荣生物科技有限公司持有相当数量的股份。这可以表明该公司在投资界具有一定的公信力。然而,最好警惕依赖机构投资者带来的所谓验证。他们也一样,有时也会犯错。如果两个大型机构投资者试图同时抛售一只股票,股价大幅下跌的情况并不少见。因此,值得查看一下上海雪荣生物科技有限公司过去的盈利轨迹(见下图)。当然,请记住,还有其他因素需要考虑。
深交所:2022年9月30日收益和收入增长300511对冲基金在上海雪荣生物科技股份有限公司的股份并不多。看看我们的数据,我们可以看到,第一大股东是持有21%流通股的CEO杨永平。浙江投资股权投资管理有限公司和深圳市云图资产管理服务有限公司分别持有4.4%和4.3%的流通股,是第二大和第三大股东。
更深入地研究我们的所有权数据就会发现,前25名股东总共持有的股份不到登记册的一半,这表明有一大群小股东,没有单一股东占多数。
虽然研究一家公司的机构持股可以增加你的研究价值,但研究分析师的建议以更深入地了解一只股票的预期表现也是一个很好的做法。据我们所知,没有分析师对该公司的报道,所以它很可能在雷达下飞行。
上海雪荣生物科技有限公司内部人持股
公司内部人的定义可能是主观的,而且在不同的司法管辖区之间确实有所不同。我们的数据反映了个别内部人士,至少捕捉到了董事会成员。公司管理层对董事会负责,董事会应代表股东的利益。值得注意的是,有时最高层管理人员本身也是董事会成员。
大多数人认为内部人持股是积极的,因为它可以表明董事会与其他股东很好地结盟。然而,在某些情况下,太多的权力集中在这个群体中。
我们的信息显示,内部人士持有上海雪荣生物科技有限公司的大量股份。内部人士在这项34亿元人民币的业务中持有8.28亿元人民币的股份。看到内部人士如此投资于这项业务,真是太好了。或许值得一查的是,这些内部人士最近是否一直在买入。
一般公有制
普通公众通常是个人投资者,他们持有上海雪荣生物科技有限公司59%的股份,这表明它是一只相当受欢迎的股票。这种所有权水平使更广泛的公众投资者有一定的权力影响关键政策决策,如董事会组成、高管薪酬和股息支付率。
接下来的步骤:
我发现看看到底是谁拥有一家公司是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。比如风险。每家公司都有它们,我们已经发现上海雪荣生物科技有限公司的3个警示标志(其中两个是有关的!)你应该知道。
当然了这可能不是最值得购买的股票。。因此,您可能希望看到我们的免费一组有趣的潜在客户,拥有有利的财务状况。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧